Narrows it down to 4 insiders. Timing is interesting nearly 2...

Narrows it down to 4 insiders. Timing is interesting nearly 2 weeks. Why was meeting date never disclosed? Did they know the date at the Annual meeting the week before? I wonder how long they sat on the QIDP information, enough to reward themselves boatload of options before pricing driven higher with Ann.
They considered pushing back in the minutes on something related to the Phase 3 protocol but later decided they could get SPA, that doesn’t sound as straightforward as originally indicated.
New dose (formulation) in 1702 will inform Acne Phase 3, strength of Phase 2 data concern from FDA?
With the confusion around Phase 2 US vs AUS results what was FDA comments on manufacturing process during the meeting? Response doesn’t provide closure it was intended to provide.